102 related articles for article (PubMed ID: 30993905)
1. Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases.
Wang CP; Kuhn J; Shah DP; Schmidt S; Lam YF; MacCarthy D; Tenner L; Ramirez AG
Cancer Med; 2019 Jun; 8(6):3206-3215. PubMed ID: 30993905
[TBL] [Abstract][Full Text] [Related]
2. Metformin for Reducing Racial/Ethnic Difference in Prostate Cancer Incidence for Men with Type II Diabetes.
Wang CP; Lehman DM; Lam YF; Kuhn JG; Mahalingam D; Weitman S; Lorenzo C; Downs JR; Stuart EA; Hernandez J; Thompson IM; Ramirez AG
Cancer Prev Res (Phila); 2016 Oct; 9(10):779-787. PubMed ID: 27026681
[TBL] [Abstract][Full Text] [Related]
3. Disparities in hepatocellular carcinoma incidence by race/ethnicity and geographic area in California: Implications for prevention.
Yang B; Liu JB; So SK; Han SS; Wang SS; Hertz A; Shariff-Marco S; Lin Gomez S; Rosenberg PS; Nguyen MH; Hsing AW
Cancer; 2018 Sep; 124(17):3551-3559. PubMed ID: 30113700
[TBL] [Abstract][Full Text] [Related]
4. Diabetes mellitus and metformin in hepatocellular carcinoma.
Fujita K; Iwama H; Miyoshi H; Tani J; Oura K; Tadokoro T; Sakamoto T; Nomura T; Morishita A; Yoneyama H; Masaki T
World J Gastroenterol; 2016 Jul; 22(27):6100-13. PubMed ID: 27468203
[TBL] [Abstract][Full Text] [Related]
5. Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study.
Li WQ; Park Y; McGlynn KA; Hollenbeck AR; Taylor PR; Goldstein AM; Freedman ND
Hepatology; 2014 Aug; 60(2):588-97. PubMed ID: 24715615
[TBL] [Abstract][Full Text] [Related]
6. Effect of diabetes medications and glycemic control on risk of hepatocellular cancer in patients with nonalcoholic fatty liver disease.
Kramer JR; Natarajan Y; Dai J; Yu X; Li L; El-Serag HB; Kanwal F
Hepatology; 2022 Jun; 75(6):1420-1428. PubMed ID: 34779535
[TBL] [Abstract][Full Text] [Related]
7. Socioeconomic status and hepatocellular carcinoma in the United States.
Shebl FM; Capo-Ramos DE; Graubard BI; McGlynn KA; Altekruse SF
Cancer Epidemiol Biomarkers Prev; 2012 Aug; 21(8):1330-5. PubMed ID: 22669949
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of metformin on age related comorbidities in older men with type 2 diabetes.
Wang CP; Lorenzo C; Habib SL; Jo B; Espinoza SE
J Diabetes Complications; 2017 Apr; 31(4):679-686. PubMed ID: 28190681
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of hepatocellular carcinoma in type 2 diabetes patients: A two-centre study in a developing country.
Azit NA; Sahran S; Voon Meng L; Subramaniam M; Mokhtar S; Mohammed Nawi A
PLoS One; 2021; 16(12):e0260675. PubMed ID: 34882716
[TBL] [Abstract][Full Text] [Related]
10. Race/ethnicity and sex differences in the association between area-level arsenic exposure concentration and hepatocellular carcinoma (HCC) incidence rates in Texas. An ecological study.
Oluyomi AO; Thrift AP; Olayode A; Symanski E; Roy H; El-Serag HB
Environ Res; 2024 Jan; 240(Pt 2):117538. PubMed ID: 37926230
[TBL] [Abstract][Full Text] [Related]
11. Future of Hepatocellular Carcinoma Incidence in the United States Forecast Through 2030.
Petrick JL; Kelly SP; Altekruse SF; McGlynn KA; Rosenberg PS
J Clin Oncol; 2016 May; 34(15):1787-94. PubMed ID: 27044939
[TBL] [Abstract][Full Text] [Related]
12. Incident Hepatocellular Carcinoma Risk in Patients Treated with a Sulfonylurea: A Nationwide, Nested, Case-Control Study.
Lee JY; Jang SY; Nam CM; Kang ES
Sci Rep; 2019 Jun; 9(1):8532. PubMed ID: 31189966
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 outcomes, risk factors and associations by race: a comprehensive analysis using electronic health records data in Michigan Medicine.
Gu T; Mack JA; Salvatore M; Sankar SP; Valley TS; Singh K; Nallamothu BK; Kheterpal S; Lisabeth L; Fritsche LG; Mukherjee B
medRxiv; 2020 Jun; ():. PubMed ID: 32793920
[TBL] [Abstract][Full Text] [Related]
14. Neighborhood-Level Factors Contribute to Disparities in Hepatocellular Carcinoma Incidence in Texas.
Oluyomi AO; El-Serag HB; Olayode A; Thrift AP
Clin Gastroenterol Hepatol; 2023 May; 21(5):1314-1322.e5. PubMed ID: 35933074
[TBL] [Abstract][Full Text] [Related]
15. Racial disparities in stroke incidence in the Women's Health Initiative: Exploring biological, behavioral, psychosocial, and social risk factors.
Calancie L; Leng XI; Whitsel EA; Cené C; Hassmiller Lich K; Dave G; Corbie G
SSM Popul Health; 2024 Mar; 25():101570. PubMed ID: 38313870
[TBL] [Abstract][Full Text] [Related]
16. Temporal Trends of Health Disparity in the Utilization of Curative-Intent Treatments for Hepatocellular Carcinoma- Are we making progress?
Agudile EP; Vega EA; Salirrosas O; Agudile UM; Chirban AM; Lathan C; Sorescu GP; Odisio BC; Panettieri E; Conrad C
J Gastrointest Surg; 2024 May; ():. PubMed ID: 38754809
[TBL] [Abstract][Full Text] [Related]
17. Racial and Ethnic Disparities in Barriers to Care in Patients with Hepatocellular Carcinoma.
Schoenberger H; Rich NE; Jones P; Yekkaluri S; Yopp A; Singal AG;
Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1094-1096.e2. PubMed ID: 34965448
[TBL] [Abstract][Full Text] [Related]
18. Geographic hotspot detection for late-stage hepatocellular carcinoma: novel approach to cancer control.
Zhou K; Thompson LK; Liu L; Terrault NA; Cockburn MG
Cancer Causes Control; 2022 May; 33(5):701-710. PubMed ID: 35084657
[TBL] [Abstract][Full Text] [Related]
19. Burden of hepatocellular carcinoma among hispanics in South Texas: a systematic review.
Ha J; Chaudhri A; Avirineni A; Pan JJ
Biomark Res; 2017; 5():15. PubMed ID: 28439416
[TBL] [Abstract][Full Text] [Related]
20. Race/ethnic associations with comprehensive cancer center access and clinical trial enrollment for acute leukemia.
Hantel A; Brunner AM; Plascak JJ; Uno H; Varela JC; Luskin MR; Rebbeck TR; Stone RM; Lathan CS; DeAngelo DJ; Abel GA
J Natl Cancer Inst; 2024 Mar; ():. PubMed ID: 38518098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
